Brian McVeigh
Vorstandsvorsitzender bei Code Biotherapeutics, Inc.
Profil
Brian P.
McVeigh is the founder of Code Biotherapeutics, Inc. He currently holds multiple positions including Executive Chairman at Redpin Therapeutics, Inc., Director at Genisphere LLC, Member at Licensing Executives Society, Strategic Advisor at IP Group Plc, Senior Advisor at UPMC Enterprises, Venture Partner & USA at 4BIO Ventures Management Ltd., Strategic Advisor at SciNeuro Pharmaceuticals, President at SG3 Ventures LLC, and Strategic Advisor at Longview Innovation.
Previously, he served as Chief Executive Officer & Director at KBP Biosciences USA, Inc., Chief Business Officer at Zafgen, Inc., and Vice President-Investment Management at GSK Plc.
Mr. McVeigh obtained his undergraduate degree from LaSalle University and his MBA from Villanova University.
Aktive Positionen von Brian McVeigh
Unternehmen | Position | Beginn |
---|---|---|
Licensing Executives Society | Corporate Officer/Principal | - |
Genisphere LLC
Genisphere LLC Electronic Equipment/InstrumentsElectronic Technology Genisphere LLC manufactures kits and reagents used for the ultra-sensitive detection of nucleic acids and proteins. Its solutions are primarily based on its proprietary whole transcriptome RNA Amplification processes, miRNA labeling methodologies, and 3DNA Dendrimer Nanotechnology. The firm's combined technologies permit the interrogation and ultra-sensitive detection of a wide range of biomolecules on a variety of detection platforms, including microarrays, flow and bead based assays, ELISAs, lateral flow assays and RNA sequencing. The company was founded in 1997 and is headquartered in Hatfield, PA. | Direktor/Vorstandsmitglied | 06.12.2018 |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Vorstandsvorsitzender | - |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Private Equity Investor | 01.06.2020 |
Redpin Therapeutics, Inc.
Redpin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY. | Vorsitzender | 01.04.2021 |
UPMC Enterprises
UPMC Enterprises Investment ManagersFinance UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania. | Berater | 01.11.2020 |
Scineuro Pharmaceuticals
Scineuro Pharmaceuticals BiotechnologyHealth Technology SciNeuro Pharmaceuticals is a Chinese clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. SciNeuro Pharmaceuticals is based in Shanghai, China, and has corporate and R&D facilities located in both Shanghai and Beijing. SciNeuro has built a portfolio of pipeline programs that address three key disease-driving mechanisms of neurodegeneration. The company is committed to delivering medicines that can make a difference in the lives of patients around the world. The company is an innovation-driven, neuroscience-focused biopharmaceutical company that uses in-house discovery and development to create innovative therapeutics for neurodegenerative and other CNS diseases. The company was founded in 2020 by Min Li, who has been the CEO since then. | Berater | 01.03.2020 |
IP Group Plc /Venture Capital/
IP Group Plc /Venture Capital/ Investment ManagersFinance IP Group Plc /Venture Capital/ (IP Group) is a venture capital subsidiary of IP Group Plc founded in 2001. The firm is headquartered in London, United Kingdom. | Berater | - |
SG3 Ventures LLC | Präsident | 01.01.2018 |
Ehemalige bekannte Positionen von Brian McVeigh
Unternehmen | Position | Ende |
---|---|---|
░░░ ░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░ | ░░░░░ ░░░░░░░░░░ ░░░░░░░ | - |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Brian McVeigh
LaSalle University | Undergraduate Degree |
Villanova University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
GSK PLC | Health Technology |
Private Unternehmen | 11 |
---|---|
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Licensing Executives Society | |
Genisphere LLC
Genisphere LLC Electronic Equipment/InstrumentsElectronic Technology Genisphere LLC manufactures kits and reagents used for the ultra-sensitive detection of nucleic acids and proteins. Its solutions are primarily based on its proprietary whole transcriptome RNA Amplification processes, miRNA labeling methodologies, and 3DNA Dendrimer Nanotechnology. The firm's combined technologies permit the interrogation and ultra-sensitive detection of a wide range of biomolecules on a variety of detection platforms, including microarrays, flow and bead based assays, ELISAs, lateral flow assays and RNA sequencing. The company was founded in 1997 and is headquartered in Hatfield, PA. | Electronic Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Health Technology |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Finance |
Redpin Therapeutics, Inc.
Redpin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY. | Commercial Services |
UPMC Enterprises
UPMC Enterprises Investment ManagersFinance UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania. | Finance |
Scineuro Pharmaceuticals
Scineuro Pharmaceuticals BiotechnologyHealth Technology SciNeuro Pharmaceuticals is a Chinese clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. SciNeuro Pharmaceuticals is based in Shanghai, China, and has corporate and R&D facilities located in both Shanghai and Beijing. SciNeuro has built a portfolio of pipeline programs that address three key disease-driving mechanisms of neurodegeneration. The company is committed to delivering medicines that can make a difference in the lives of patients around the world. The company is an innovation-driven, neuroscience-focused biopharmaceutical company that uses in-house discovery and development to create innovative therapeutics for neurodegenerative and other CNS diseases. The company was founded in 2020 by Min Li, who has been the CEO since then. | Health Technology |
IP Group Plc /Venture Capital/
IP Group Plc /Venture Capital/ Investment ManagersFinance IP Group Plc /Venture Capital/ (IP Group) is a venture capital subsidiary of IP Group Plc founded in 2001. The firm is headquartered in London, United Kingdom. | Finance |
KBP Biosciences USA, Inc.
KBP Biosciences USA, Inc. Miscellaneous Commercial ServicesCommercial Services KBP Biosciences engages in conducting biotechnological research to develop therapies for patients. The company was founded by Huang Zhenhua in and is headquartered in Princeton, NJ. | Commercial Services |
SG3 Ventures LLC |